<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889667</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-009</org_study_id>
    <secondary_id>ORMD-0801</secondary_id>
    <nct_id>NCT01889667</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With T2DM Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and pharmacodynamics of an oral formulation
      of insulin in subjects with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, Phase II(a), randomized, double-blind, placebo-controlled, parallel
      group, inpatient study preceded by a 5-day single-blind outpatient placebo run-in period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Safety and Tolerability of ORMD-0801.</measure>
    <time_frame>Eight (8) days</time_frame>
    <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</measure>
    <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
    <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</measure>
    <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
    <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</measure>
    <time_frame>Screening, Day 2. Day 9</time_frame>
    <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</measure>
    <time_frame>Screening, Day 2, Day 9</time_frame>
    <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Insulin Formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oil Capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 1</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 1</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORMD-0801 Dose # 2</intervention_name>
    <description>Oral Insulin Formulation</description>
    <arm_group_label>ORMD-0801 Dose # 2</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oil Capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, age 20 to 70 years, inclusive with T2DM;

          -  At randomization, patients are treated for diabetes by diet and exercise, or by diet,
             exercise and metformin (&gt;1000 mg/day; any type and regimen). Patients on a stable
             regimen of metformin (defined as the same metformin dose and type) for at least 6
             weeks prior to entering the placebo run-in period. Other anti-diabetic agents not in
             use for the 6 weeks prior to entering the placebo run-in period;

          -  25 kg/m2 ≤ BMI ≤ 40 kg/m2

          -  6.5% ≤ HbA1c ≤ 10.5%, prior to randomization)

          -  Fasting plasma glucose ≥ 126 mg/dL (8.3 mmo1/L) prior to randomization;

          -  No tobacco or nicotine use within 10 wks prior to screening;

          -  Females of child-bearing potential must have a negative serum pregnancy test result at
             screening and a negative urine pregnancy test at Visit 3. Females of non-childbearing
             potential are defined as postmenopausal who:

               1. had more than 24 months since last menstrual cycle with menopausal levels of FSH;

               2. age &gt; 55 years old; or

               3. are surgically menopausal.

        Exclusion Criteria:

          -  Presence of any clinically significant endocrine disease according to the PI;

          -  Clinical diagnosis of T1DM;

          -  Fasting plasma glucose &gt; 260 mg/dL at the end of washout/stabilization/run-in periods;

          -  Evidence of unawareness of hypoglycemia, a documented plasma glucose ≤ 50 mg/dL in the
             absence of symptoms of hypoglycemia;

          -  Presence of any clinically significant condition that might interfere with the
             evaluation of study medication;

          -  Presence or history of cancer within the past 5 yrs. with the exception of
             adequately-treated localized basal cell skin cancer or in situ uterine cervical
             cancer;

          -  Laboratory abnormalities at screening:

               1. C-peptide &lt; 1.0 ng/mL;

               2. Positive pregnancy test in females of childbearing potential (at screening and
                  start of run-in period);

               3. Abnormal TSH levels &gt; 1.5 x the upper limit of normal;

               4. Positive test for hepatitis B surface antigen and/or hepatitis C antibody;

               5. Positive test for HIV;

               6. Any relevant abnormality interfering with the efficacy or the safety assessments
                  during study drug administration;

          -  Use of the following medications

               1. History of use of insulin for no more than 1 wk in the last 6 mos and none in the
                  last 6 wks prior to randomization;

               2. History of use of aprotinin at any time prior to the screening visit;

               3. Administration of anti-diabetic drugs other than metformin within 6 wks prior to
                  run-in period;

               4. Administration of thiazolidinedione treatment within 3 months prior to
                  randomization;

               5. Administration of thyroid preparations or thyroxine (except in patients on stable
                  replacement therapy) within 6 weeks prior to screening visit;

               6. Administration of systemic long-acting corticosteroids within two months or
                  prolonged use of other systemic corticosteroids or inhaled corticosteroids within
                  30 days prior to screening visit;

               7. Use of medications known to modify glucose metabolism or to decrease the ability
                  to recover from hypoglycemia such as oral, parenteral, and inhaled steroids, beta
                  blockers (with the exception of beta blocker ophthalmic solutions for glaucoma or
                  ocular hypertension), and immunosuppressive or immunomodulating agents.

          -  History of severe or multiple allergies;

          -  History of tobacco or nicotine use within 10 wks prior to screening

          -  Patient is on a weight loss program and is not in the maintenance phase, or patient
             that started weight loss medication within 8 wks prior to screening;

          -  Pregnancy or breast-feeding;

          -  Patient has a screening visit systolic blood pressure of ≥165 mm Hg or diastolic blood
             pressure of ≥100 mm Hg. Patients will be allowed to take a BP rescue medication as
             long as it does not affect glucose metabolism (e.g., diuretics) or sensation of
             hypoglycemia (e.g., beta-blockers);

          -  Patient is, at the time of signing informed consent, a user of recreational or illicit
             drugs or has had a recent history (within the last year) of drug or alcohol abuse or
             dependence;

          -  Elevated liver enzymes ALT, AST, alkaline phosphatase) &gt; 2 x the upper limit of normal
             at screening;

          -  Very high triglyceride level (&gt;600 mg/dL) at screening;

          -  ECG abnormality at screening or CV. Clinically significant CV will include

               1. history of stroke, transient ischemic attack, or MCI within 6 months prior to
                  screening;

               2. history of or currently have NYHA Class II-IV heart failure prior to screening;
                  or

               3. uncontrolled hypertension defined as BP ≥180 mmHg (systolic) or ≥110 mmHG
                  (diastolic) at screening or at Visit 2;

          -  One or more contraindications to metformin;

          -  History of gastrointestinal disorders with the potential to interfere with drug
             absorption;

        At the Principal Investigator's discretion, any condition or other factor that is deemed
        unsuitable for patient enrollment into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel M Neutel, M. D.</last_name>
    <role>Study Director</role>
    <affiliation>Orange County Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <results_first_submitted>April 28, 2014</results_first_submitted>
  <results_first_submitted_qc>October 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2014</results_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Insulin</keyword>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation</description>
        </group>
        <group group_id="P2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Oil Capsules
Placebo: Oil Capsules</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
        </group>
        <group group_id="B2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Oil Capsules
Placebo: Oil Capsules</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="4.9"/>
                    <measurement group_id="B2" value="57.4" spread="4.7"/>
                    <measurement group_id="B3" value="53.6" spread="12.0"/>
                    <measurement group_id="B4" value="55.3" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Safety and Tolerability of ORMD-0801.</title>
        <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
        <time_frame>Eight (8) days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Safety and Tolerability of ORMD-0801.</title>
          <description>Number of Hypoglycemic events, serious adverse events, and adverse events related to the study drug</description>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
        <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
        <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
        <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Mean Night Time Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
          <description>Difference between concentration of Nightime Glucose of patients on Placebo and concentration of Nightime Glucose of patients on ORMD-0801</description>
          <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
          <units>mg/DL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Last two days (day 6 and day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.64" spread="39.400"/>
                    <measurement group_id="O2" value="150.24" spread="49.264"/>
                    <measurement group_id="O3" value="167.95" spread="64.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Seven Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.73" spread="38.861"/>
                    <measurement group_id="O2" value="149.38" spread="38.249"/>
                    <measurement group_id="O3" value="165.85" spread="60.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
        <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
        <time_frame>Seven (7) days, and last two days (Day 6 and day 7)</time_frame>
        <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Mean Daytime Glucose as Measured by Contiuous Glucose Monitoring (CGM)</title>
          <description>Difference between concentration of Mean Daytime Glucose of patients on Placebo and concentration of Mean Daytime Glucose of patients on ORMD-0801</description>
          <population>Per Protocol (PP) population, consisting of all study completers with an endpoint of adequate weighted mean nighttime glucose and no major protocol violations</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Seven Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.55" spread="36.986"/>
                    <measurement group_id="O2" value="163.05" spread="30.282"/>
                    <measurement group_id="O3" value="175.99" spread="61.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last two days (day 6 and day 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.23" spread="40.160"/>
                    <measurement group_id="O2" value="158.58" spread="40.672"/>
                    <measurement group_id="O3" value="176.06" spread="63.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</title>
        <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
        <time_frame>Screening, Day 2. Day 9</time_frame>
        <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Morning Fasting Serum Insulin</title>
          <description>Difference between concentration of Morning fasting serum insulin of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
          <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.80" spread="18.984"/>
                    <measurement group_id="O2" value="17.34" spread="12.225"/>
                    <measurement group_id="O3" value="34.51" spread="64.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.93" spread="10.122"/>
                    <measurement group_id="O2" value="12.94" spread="7.472"/>
                    <measurement group_id="O3" value="9.01" spread="4.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.70" spread="8.559"/>
                    <measurement group_id="O2" value="15.51" spread="14.924"/>
                    <measurement group_id="O3" value="9.85" spread="3.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</title>
        <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
        <time_frame>Screening, Day 2, Day 9</time_frame>
        <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801 Dose # 1</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation 8mg + 8 mg capsules</description>
          </group>
          <group group_id="O2">
            <title>ORMD-0801 Dose # 2</title>
            <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation 8 mg + 16 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Oil Capsules
Placebo: Oil Capsules</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of ORMD-0801 on Morning Fasting C-peptide Compared to Placebo</title>
          <description>Difference between concentration of Morning fasting C-peptide of patients on Placebo and concentration of Morning fasting C-peptide of patients on ORMD-0801</description>
          <population>Modified intention-to-treat (mITT) population consisting of all randomized patients who took at least one dose of study medication and who had at least one night of CGM monitoring</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.233" spread="2.3869"/>
                    <measurement group_id="O2" value="3.125" spread="1.3372"/>
                    <measurement group_id="O3" value="5.159" spread="4.9825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.180" spread="1.6593"/>
                    <measurement group_id="O2" value="3.064" spread="0.9200"/>
                    <measurement group_id="O3" value="2.400" spread="0.9419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.875" spread="1.6927"/>
                    <measurement group_id="O2" value="3.090" spread="1.1021"/>
                    <measurement group_id="O3" value="2.715" spread="0.8506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ORMD-0801 Dose # 1</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 1: Oral Insulin Formulation (16 mg)</description>
        </group>
        <group group_id="E2">
          <title>ORMD-0801 Dose # 2</title>
          <description>Oral Insulin Formulation
ORMD-0801 Dose # 2: Oral Insulin Formulation (24 mg)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Oil Capsules
Placebo: Oil Capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>number</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer</name_or_title>
      <organization>Oramed</organization>
      <phone>+972-2-566-0001</phone>
      <email>aviva@oramed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

